Eculizumab
- Generic Name
- Eculizumab
- Brand Names
- Soliris, Epysqli, Bekemv
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 219685-50-4
- Unique Ingredient Identifier
- A3ULP0F556
- Background
Eculizumab is a monoclonal antibody that targets complement protein C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.
...
- Indication
Eculizumab is indicated in the US to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy, and neuromyelitis optica spectrum disorder (NMOSD). It is also indicated in EU to treat PNH in both adult and pediatric patients.
- Associated Conditions
- Generalized Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorders, Paroxysmal Nocturnal Haemoglobinuria (PNH), Thrombotic Microangiopathies
- Associated Therapies
- -
Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- First Posted Date
- 2004-12-06
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 75
- Registration Number
- NCT00098280
- Locations
- 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.